Navigation Links
New device to remove stroke-causing blood clots proves better than standard tool
Date:8/26/2012

Stroke is the fourth leading cause of death and a common cause of long-term disability in the United States, but doctors have very few proven treatment methods. Now a new device that mechanically removes stroke-causing clots from the brain is being hailed as a game-changer.

In a recent clinical trial, the SOLITAIRE Flow Restoration Device dramatically outperformed the standard mechanical treatment. Findings from the trial, called SOLITAIRE With the Intention for Thrombectomy (SWIFT), are published online today in the journal The Lancet and will also appear in a later print edition of the journal.

SOLITAIRE, which was approved by the U.S. Food and Drug Administration in March, is among an entirely new generation of devices designed to remove blood clots from blocked brain arteries in patients experiencing an ischemic stroke. It has a self-expanding, stent-like design, and once inserted into a blocked artery using a thin catheter tube, it compresses and traps the clot. The clot is then removed by withdrawing the device, reopening the blocked blood vessel.

"This new device is significantly changing the way we can treat ischemic stroke," said the study's lead author, Dr. Jeffrey L. Saver, director of the UCLA Stroke Center and a professor of neurology at the David Geffen School of Medicine at UCLA. "We are going from our first generation of clot-removing procedures, which were only moderately good in reopening target arteries, to now having a highly effective tool."

Results of the study showed that the device opened blocked vessels without causing symptomatic bleeding in or around the brain in 61 percent of patients. The standard FDAapproved mechanical device a corkscrew-type clot remover called the MERCI Retriever was effective in 24 percent of cases. The use of SOLITAIRE also led to better survival three months after a stroke. There was a 17.2 percent mortality rate with the new device, compared with a 38.2 percent rate with the older one.

About 87 percent of all strokes are caused by blood clots blocking a blood vessel supplying the brain. The stroke treatment that has received the most study is an FDAapproved clot-busting drug known as tissue plasminogen activator, but this drug must be given within four-and-a-half hours of the onset of stroke symptoms, and even more quickly in older patients.

When clot-busting drugs cannot be used or are ineffective, the clot can sometimes be mechanically removed during, or beyond, the four-and-a-halfhour window. The current study, however, did not compare mechanical clot removal to drug treatment.

For the trial, researchers randomly assigned 113 stroke patients at 18 hospitals to receive either SOLITAIRE or MERCI therapy within eight hours of stroke onset, between January 2010 and February 2011. The patients' average age was 67, and 68 percent were male. The time from the beginning of stroke symptoms to the start of the clot-retriever treatment averaged 5.1 hours. Forty percent of the patients had not improved with standard clot-busting medication prior to the study, while the remainder had not received it.

At the suggestion of a safety monitoring committee, the trial was ended nearly a year earlier than planned due to significantly better outcomes with the experimental device.

Other statistically significant findings included:

  • 2 percent of SOLITAIRE-treated patients had symptoms of bleeding in the brain, compared with 11 percent of MERCI patients.
  • At the 90-day follow-up, overall adverse event rates, including bleeding in the brain, were similar for the two devices.
  • 58 percent of SOLITAIRE-treated patients had good mental/motor functioning at 90 days, compared with 33 percent of MERCI patients.
  • The SOLITARE device also opened more vessels when used as the first treatment approach, necessitating fewer subsequent attempts with other devices or drugs.

"Nearly a decade ago, our UCLA Stroke Center team invented the first stroke retrieval device the MERCI Retriever and now we are pleased to have helped develop and successfully test a superior, next-generation clot removing device," said Dr. Reza Jahan, associate professor of radiology at UCLA and the study's principal neurointerventional investigator, who also led the pre-clinical studies. "It is exciting to have a highly effective new tool that can improve the outcomes for more stroke patients."


'/>"/>

Contact: Amy Albin
aalbin@mednet.ucla.edu
310-794-8672
University of California - Los Angeles Health Sciences
Source:Eurekalert  

Related medicine news :

1. Study: Clot removal devices successful tools for acute ischemic stroke treatment
2. Could FastStitch device be the future of suture?
3. Retinal Device Restores Sight to Blind Mice
4. Mechanical Device Helps Kids Waiting for Heart Transplant
5. Unprecedented accuracy in locating brain electrical activity with new device
6. Cell-Based Tracking Devices Might Help Monitor Treatments
7. Device converting images into music helps individuals without vision reach for objects in space
8. New Home Energy Savings Device Poised to Help Thousands Succeed Working from Home
9. Corporate Whistle Blower Center Now Urges Medical Device Insiders To Be A Whistleblower If They Can Prove The Device Maker Knew Of A Failure & Said Nothing=Huge Rewards
10. Vygone Presents a Revolutionary Electro Waveform Device to Help Treat Molluscum Contagiosum Lesions
11. Magnets in iPad2 May Alter Settings on Brain Shunt Devices: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New device to remove stroke-causing blood clots proves better than standard tool
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... ... 4th-year medical students improve their chances of acceptance to a residency in a ... who have earned degrees outside the U.S. , According to data released by ...
(Date:7/21/2017)... ... July 21, 2017 , ... In the first prospective ACL ... Orthopaedics Outcome Network (MOON) demonstrated that patients could perform sports-related functions and maintain ... decline over time. The study, presented today at the American Orthopaedic Society ...
(Date:7/20/2017)... ... , ... ChenMed , a leading provider of value-based care for seniors, ... as Richmond Chief Medical Officer. Dr. McCarter, formerly Associate Professor of Family Medicine ... Ambulatory Services for the UVA Health System, brings 30 years of highly relevant experience ...
(Date:7/20/2017)... ... , ... For individuals with extended hospital stays or who are residents of ... are specially designed to accommodate patients with a wide range of ailments or special ... Ind., has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features ...
(Date:7/20/2017)... , ... July 20, 2017 , ... ... to the development of non-invasive devices and systems for monitoring cardiopulmonary diseases, announced ... Proceeds will be used to complete regulatory submissions and fund final engineering and ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... -- The Institute for In Vitro Sciences (IIVS), a ... a VITROCELL® inhalation exposure system thanks to a generous ... which is designed to replace animals in inhalation testing, ... airborne test materials in an environment that mimics the ... testing combustible tobacco products, as well as next generation ...
(Date:7/10/2017)... N.C. , July 10, 2017 Locus ... Convertible Note to support the development of CRISPR-Cas3 antimicrobial ... Holdings Limited, a leading Chinese Internet services provider, and ... will advance multiple infectious disease product programs targeting antibiotic ... Founded by Dr. Rodolphe Barrangou ...
(Date:7/5/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... pharmaceutical company focused on the development of oral drug delivery ... Israel Securities Authority to dual-list its common stock on the ... trading on the TASE on July 12, 2017 under the ... Company, it is expected that Oramed will be included in ...
Breaking Medicine Technology: